1. Signaling Pathways
  2. Immunology/Inflammation
  3. STING

STING

Stimulator of Interferon Genes; TMEM173; MITA; ERIS; MPYS

Stimulator of interferon genes (STING) is an integral ER-membrane protein that can be activated by 2'3'-cGAMP synthesized by cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) upon binding of double-stranded DNA. It activates interferon (IFN) and inflammatory cytokine responses to defend against infection by microorganisms.

STING is a key cytosolic receptor for small nucleotides and plays a key role in anticancer and antiviral immunity. STING signaling pathway is also a critical link between innate and adaptive immunity, and induces anti-tumor immune responses. STING agonists, such as endogenous cyclic dinucleotide (CDN) cyclic GMP-AMP (cGAMP), have been used in diverse research for immunogenic tumor clearance, antiviral treatments and vaccine adjuvants.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-168034
    diABZI-4
    Agonist
    diABZI-4 is an oral active STING agonist with broad-spectrum antiviral activity. diABZI-4 induces the production of pro-inflammatory cytokines and lymphocyte activation by activating STING, thereby inhibiting the replication of influenza A virus (IAV), SARS-CoV-2, and human rhinovirus (HRV), with an EC50 range of 11.8-199 nM.
    diABZI-4
  • HY-173399
    hSTING activator-1
    Agonist
    hSTING activator-1 (Compound 68) is a STING agonist. hSTING activator-1 can effectively activate multiple human STING variants (R232, H232, HAQ) with EC50 values of 56 nM, 89 nM and 51 nM, respectively. hSTING activator-1 activates the type I interferon pathway by directly binding to STING protein and stabilizing its conformation, promoting downstream IRF3 phosphorylation and cytokine release. hSTING activator-1 inhibits fibrosarcoma tumor growth and has potential in cancer research.
    hSTING activator-1
  • HY-154850
    F-CRI1
    Agonist
    F-CRI1 is a potent STING agonist with a Kd value of 40.62 nM. F-CRI1 is a radioactive probe with 18F-labeled modification. F-CRI1 can be used to study STING visualization in the tumor microenvironment.
    F-CRI1
  • HY-162133
    MSA-2-Pt
    Agonist
    MSA-2-Pt is an orally active STING agonist that has good cell membrane permeability. MSA-2-Pt can induce cell death by Pt, which may release damaged DNA to activate the cGAS-STING pathway. Besides, MSA-2-Pt can activate the STING pathway directly by MSA-2. MSA-2-Pt can be used for the research of cancer.
    MSA-2-Pt
  • HY-152962
    STING agonist-29
    Agonist
    STING agonist-29 (CF511) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, exhibits activity against SARS-CoV series strains.
    STING agonist-29
  • HY-172671
    STING agonist-43
    Agonist
    STING agonist-43 (Compound 67) is a selective STING agonist (EC50: 20.53 μM). STING agonist-43 selectively amplifies cGAMP-dependent STING pathway activation by modulating STING oligomerization. B16.F10 has antitumor activity in a mouse melanoma model. STING agonist-43 can be used for the study of cancer immunity.
    STING agonist-43
  • HY-149781
    STING agonist-34
    Agonist
    STING agonist-34 (Compound 12L) is a potent STING agonist with an IC50 value of 1.15 μM and an EC50 of 0.38 μM in THP1 cells. STING agonist-34 could be used in cancer research.
    STING agonist-34
  • HY-168887
    ZSA-51
    Agonist
    ZSA-51 is a potent and orally active STING agonist. ZSA-51 shows anticancer activity. ZSA-51 remodeles immune microenvironment both in tumor and lymph node.
    ZSA-51
  • HY-152958
    STING agonist-25
    Agonist
    STING agonist-25 (CF505) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, TBK1 and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains.
    STING agonist-25
  • HY-19943
    TLC388
    Agonist
    TLC388 is a novel camptothecin analog with limited antitumor activity in metastatic NEC.
    TLC388
  • HY-139179
    STING agonist-14
    Agonist
    STING agonist-14 (compound 12b) is a potent STING agonist that is efficacious across species. STING agonist-14 could activate the pathway by directly binding human STING. STING agonist-14 can be used for the research of tumours or viral infections.
    STING agonist-14
  • HY-149267
    STING agonist-30
    Agonist
    STING agonist-30 is a potent STING agonist. STING agonist-30 exhibits STING-dependent immune activation. STING agonist-30 has extensive inhibitory effects on various viruses, including the herpes simplex virus (HSV), rotavirus, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
    STING agonist-30
  • HY-148546
    STING agonist-21
    Agonist
    STING agonist-21 (compound 1) is a STING agonist, with an EC50 of 592.8 nM. STING agonist-21 can be used for cancer research.
    STING agonist-21
  • HY-10964R
    Vadimezan (Standard)
    Agonist
    Vadimezan (Standard) (DMXAA (Standard)) is the analytical standard of Vadimezan (HY-10964). This product is intended for research and analytical applications. Vadimezan (DMXAA; ASA-404), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan is unable to activate human STING. Vadimezan has anti-influenza virus H1N1-PR8 activities.
    Vadimezan (Standard)
  • HY-139586B
    Ulevostinag (isomer 2)
    Agonist
    Ulevostinag isomer 2 (MK-1454 isomer 2) is the isomer of Ulevostinag. Ulevostinag is a STING agonist.
    Ulevostinag (isomer 2)
  • HY-158711
    STING agonist-38
    Agonist
    STING agonist-38 (compound 58) is a potent agonist of STING, with the EC50 of 0.05 μM in THP1 cells. STING agonist-38 has certain oral bioactivity.
    STING agonist-38
  • HY-168803
    BDW-OH
    Agonist
    BDW-OH is an active metabolite of BDW568 (HY-162465 ). BDW568 is a STING agonist that can selectively activate the human STINGA230 allele.
    BDW-OH
  • HY-164919
    Calotatug ginistinag
    Agonist
    Calotatug ginistinag (XMT-2056) is an antibody-drug conjugate targeting HER2, with an effective payload connected via a linker (LP, HY-148067) to a STING agonist (STING agonist-20, HY-148068), and has potential immune activation and anticancer activity.
    Calotatug ginistinag
  • HY-168384
    M04
    Agonist
    M04 is an agonist of STING. It induces the expression of the IFN reporter gene in HEK293T cells expressing wild-type human STING, but does not induce this expression in HEK293T cells expressing the R71H-G230A-R293Q (HAQ) STING variant or in mouse RAW 264.7 cells, indicating that its activity is dependent on allelic and species variations. M04 induces the production of TNF-α, IL-10, IL-1β, and IL-12p70 in human peripheral blood mononuclear cells (PBMCs). At a concentration of 50 µM, M04 stimulates dendritic cells isolated from PBMCs to express the MHC class II cell surface receptor HLA-DR and co-stimulatory molecules CD40, CD80, and CD86, and also enhances their ability to activate T cells in an ex vivo assay. M04 can be used in research on inflammatory immune diseases.
    M04
  • HY-139586C
    Ulevostinag (isomer 3)
    Agonist
    Ulevostinag (isomer 3) (example 246) is a potent cyclic dinucleotide agonist stimulator of interferon genes (STING). Ulevostinag (isomer 3) plays an important role in anti-tumor research.
    Ulevostinag (isomer 3)
Cat. No. Product Name / Synonyms Application Reactivity